BOULDER, CO – CaliberMRI, a startup focused on transforming MRI technology, received a $1.72 million grant from the National Cancer Institute, part of the NIH, to mature and test its quantitative MRI (qMRI) technology, the qCal-MR platform, at 12 ISPY 2 clinical sites. The focus of ISPY 2 clinical trial is the rapid evaluation of neoadjuvant (before surgery) drug treatments of breast cancer.

CaliberMRI, the University of California at San Francisco (UCSF), and the National Institute of Standards and Technology (NIST) are partnered to develop the qCal-MR based on prior joint research and development.

qCal-MR aims to remedy one of the most glaring problems in MRI practice: standardization and quantification of the qMRI image output so that, for example, breast cancer diagnostics, monitoring, and treatment efficacy assessment could be made independent of particular MRI device performance and protocols used. qCal-MR will save breast cancer patients from unnecessary, costly, and invasive procedures.

Traditional MRI scans can result in a 40% variability between readings on different equipment. The results can be costly and misleading, as cancer can go undiagnosed or misdiagnosed. qCal-MR standardizes all MRI equipment currently used in research and clinical settings using a combination of hardware reference standards called phantoms and machine learning software systems.

Dr. Todor Karaulanov, Principal Investigator on the NIH grant, says, “CaliberMRI staff, in partnership with UCSF and NIST, is very excited to take on the mandate provided by the National Cancer Institute grant to enable true quantitative MRI measurements. The successful implementation of qCal-MR in the paradigm-shifting I-SPY 2 clinical trial will help qualify breast cancer drugs by removing variability in MRI equipment and protocols.”

CaliberMRI is a subsidiary company of High Precision Devices, both based in Boulder, Colorado. Founded in 2017, CaliberMRI is focused on transforming medical imaging through quantification and standardization of traditional MRI equipment.

More information about CaliberMRI can be found at

Related Articles

Boulder-based CaliberMRI on pace to provide next-generation quality control for MRI scanners worldwide

Nov. 18, 2021 — CaliberMRI, today announced a major milestone in transforming MR imaging into an objective scientific practice using quantitative MRI. Combining its unparalleled NIST-traceable imaging phantom products and automated quality control…

CaliberMRI Receives State Grant for Biomimetic Quantitative MRI Development

Boulder, Colorado — CaliberMRI is honored to announce it has been awarded an Early-Stage  Capital and Retention grant through the Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industries Accelerator program. This funding will help further quantitative Magnetic Resonance Imaging (qMRI) through the development of biomimetic phantoms for use in breast cancer treatment and therapy monitoring. […]

CaliberMRI Named a Colorado Companies to Watch Winner

CaliberMRI (CMRI) announced today that it has been named a Colorado Company to Watch, acknowledging the drive, excellence, and influence of CMRI as a growing company in the state. Colorado Companies to Watch honors second-stage companies that develop…